37 results on '"Kaul, Anupma"'
Search Results
2. Renal Transplantation in Rare Monogenic Urinary Stone Disease - A Single-center Experience.
- Author
-
Shanmugam, Sabarinath, Prasad, Narayan, Bhadauria, Dharmendra, Kaul, Anupma, Patel, Manas Ranjan, Behera, Manas Ranjan, Kushwaha, Ravi Shankar, and Yachha, Monika
- Published
- 2024
- Full Text
- View/download PDF
3. Antibody response to ChAdOx1 nCoV‐19 (Covishield®) vaccine in people on maintenance hemodialysis.
- Author
-
Bhadauria, Dharmendra Singh, Tiwari, Prachi, Goel, Amit, Katiyar, Harshita, Kaul, Anupma, Mayank, Aggarwal, Amita, Verma, Alka, Khetan, Dhiraj, Yachha, Monika, Behera, Manas Ranjan, Yadav, Brijesh, Agarwal, Kartik, and Prasad, Narayan
- Subjects
ANTIBODY formation ,COVID-19 ,RENAL replacement therapy ,VACCINES ,COVID-19 vaccines - Abstract
Introduction: People on renal replacement therapy (RRT) have a high risk of COVID‐19 infection and subsequent death. COVID‐19 vaccination is strongly recommended for those on RRT. Data are limited on the immune response of the ChAdOx1 nCoV‐19/AZD1222 (Covishield®) vaccine in patients on RRT. Methods: A prospective cohort of adult (age > 18 years), on RRT in the form of hemodialysis were included and received two intramuscular doses of Covishield®. A blood specimen of 5.0 mL was collected at two time points, within a few days before administering the first dose of the vaccine and at 4–16 weeks after the second dose. According to their prior COVID‐19 infection status, the participants were grouped as (i) prior symptomatic COVID‐19 infection, (ii) prior asymptomatic COVID‐19 infection, and (iii) no prior COVID‐19 infection. Results: A large proportion (81%) of participants had anti‐spike antibodies (ASAb) before vaccination, and a reasonable proportion (30%) also had neutralizing antibodies (NAb). The titer of ASAb was relatively low (207 U/mL) before vaccination. The ASAb titer (9405 [1635–25,000] U/mL) and percentage of NAb (96.4% [59.6–98.1%]) were markedly increased following the administration of two doses of the vaccine. The participants' prior COVID‐19 exposure status did not influence the rise in ASAb titer and NAb percentage. Further, administering two doses of the Covishield vaccine helps them achieve a high ASAb titer. Conclusion: Two doses of ChAdOx1 nCoV‐19/AZD1222 (Covishield®) vaccine, given 12 weeks apart, achieve a high titer of ASAb and a high percentage of NAb in people on hemodialysis. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. Higher pro‐inflammatory cytokines IL‐6 and IFN‐γ are associated with anti‐SARS‐CoV‐2 spike protein‐specific seroconversion in renal allograft recipients.
- Author
-
Yadav, Brijesh, Prasad, Narayan, Kushwaha, Ravi Shankar, Patel, Manas Ranjan, Bhadauria, Dharmendra, and Kaul, Anupma
- Subjects
INTERLEUKIN-6 ,SEROCONVERSION ,CYTOKINES ,ANTIBODY titer ,HOMOGRAFTS - Abstract
Background: Maintenance immunosuppressive regimens are speculated to hamper immunogenic response against severe acute respiratory syndrome‐coronavirus‐2 (SARS‐CoV‐2) in renal transplant recipients (RTRs) compared to the healthy population. Healthy people with SARS‐CoV‐2 infection often develop neutralizing antibodies and secret copious quantities of cytokines, leading to virus clearance and sometimes more severe immune‐related complications. Methods: RTRs, either acquired SARS‐CoV‐2 infection (infection group, n = 132) or were vaccinated with two vaccine doses (vaccination group, n = 78) against SARS‐CoV‐2, were recruited in the study. Thirty‐five unvaccinated RTRs, without anti‐SARS‐CoV‐2 spike protein‐specific antibodies, were also included as control. Cytokines interleukine‐6 (IL‐6), interferon‐γ (IFN‐γ), TGF‐β, and IL‐10 were measured using ELISA. The SARS‐CoV‐2 spike protein‐specific IgG‐titer was measured by chemiluminescent microparticle immunoassay methods. Results: The seroconversion rate in the infection group was 115/132 (87.12%), with a median antibody titer 706.40 au/mL (IQR, 215.45–1844.42), and in the vaccination group was 63/78 (80.76%) with antibody titer 1454.20 au/mL (IQR, 80.52–3838.75). The IL‐6, IFN‐γ, TGF‐β, and IL‐10 levels were significantly higher in both the infection and vaccination group compared to healthy control. In the infection group, pro‐inflammatory cytokines IL‐6 (55.41 ± 24.30 vs. 31.64 ± 16.98 pg/mL, p <.001) and IFN‐γ (91.21 ± 33.09 vs. 61.69 ± 33.28 pg/mL, p =.001) were significantly higher in the seroconverter group as compared to non‐seroconverter. Similarly, in the vaccination group, pro‐inflammatory cytokines IL‐6 (50.31 ± 25.67 vs. 30.00 ± 11.19 pg/mL; p =.002) and IFN‐γ (65.70 ± 39.78 vs. 32.14 ± 17.48 pg/mL; p =.001) were significantly higher in the seroconverter group compared to non‐seroconverter. In contrast, TGF‐β (820.96 ± 415.78 vs. 1045.57 ± 204.66; p =.046) was higher in non‐seroconverter. Conclusions: Pro‐inflammatory cytokines IL‐6 and IFN‐γ were significantly associated with seroconversion after SARS‐CoV‐2 infection and vaccination in RTRs. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. Clinicopathologic characteristics and outcomes of late onset lupus nephritis: a single centre experience.
- Author
-
Sharma, Harshita, Kaul, Anupma, Mohakuda, Sourya Sourabh, Behera, Manas Ranjan, Bhadauria, D. S., Agrawal, Vinita, Agarwal, Vikas, Prasad, Narayan, Singh, Anshima, and Patel, Manas Ranjan
- Subjects
LUPUS nephritis ,SYSTEMIC lupus erythematosus ,ACUTE kidney failure ,CLINICAL pathology ,CHILDBEARING age ,KIDNEY failure - Abstract
Systemic Lupus Erythematosus (SLE) occurs in the reproductive age group. Renal involvement occurs less frequently in late-onset SLE than in reproductive-age SLE patients. Here, we aimed to study the clinical, serological and histopathological characteristics of late-onset lupus nephritis (LN). Late-onset LN was defined as disease onset after 47 years of age, corresponding to the average menopausal age. Records of biopsy proven late-onset lupus nephritis patients diagnosed between June 2000 and June 2020 were reviewed. Late-onset LN constituted 53 of 4420 patients (1.2%) biopsied during the study period. Females represented 90.65% of the cohort. Mean age of the cohort was 49.5 ± 7.05 years at the time of SLE diagnosis while its renal presentation was delayed by median duration of 10 months (IQR 3–48 months). Renal failure was present in 28 patients (52.8%) with acute kidney injury (AKI) (28.3%, n = 15) as the most common presentation. On histopathological analysis, class IV was observed in 23 patients (43.5%), crescents were observed in one-third cases and lupus vasculopathy in 4 patients (7.5%). All patients received steroids. Majority of patients (43.3%; n = 23) received Euro lupus protocol for induction. On median follow up duration of 82 months, renal flares were noted in 9 patients (17%) and 8 patients (15.1%) became dialysis dependent. Among 11 patients (21%) with infectious complications, 7 patients (13.2%) suffered from tuberculosis. Infections caused three-fourth of the deaths. Late-onset lupus nephritis is rare and presents as renal failure in majority. Renal biopsy affects the clinical decision of judicious use of immunosuppression which is imperative due to high rate of infections in this cohort. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. Urinary Mitochondrial Deoxyribonucleic Acid: A Novel Biomarker of Coronavirus Disease 2019‑associated Acute Kidney Injury in Renal Transplant Recipients.
- Author
-
Yadav, Brijesh, Prasad, Narayan, Kushwaha, Ravi Shankar, Patel, Manas Ranjan, Bhadauria, Dharmendra Singh, and Kaul, Anupma
- Published
- 2023
- Full Text
- View/download PDF
7. Risk of tuberculosis among renal transplant recipients receiving rituximab therapy.
- Author
-
Chandrashekhar, Praveen, Kaul, Anupma, Bhaduaria, Dharmendra, Prasad, Narayan, Behera, Manas, Kushwaha, Ravi, Patel, Manas, Yachha, Monika, and Srivastava, Aneesh
- Subjects
KIDNEY transplantation ,RITUXIMAB ,TUBERCULOSIS ,MEDICAL protocols ,IMMUNOSUPPRESSIVE agents - Abstract
Background: Rituximab is an anti‐CD 20 agent used widely in renal transplant recipients. Its use is associated with various infections; however, its association with tuberculosis (TB) is not well established and has not been studied in post renal transplantation patients. Methods: This is a single‐center, retrospective analysis of 56 renal transplant recipients who received rituximab as a part of desensitization protocol or as rescue therapy for rejections and 287 post‐renal transplant patients who did not receive rituximab during the study period from January 2013 to June 2017. The association between use of rituximab and occurance of TB was studied. Other factors associated with TB were also investigated. Results: Baseline characteristics were similar in both the groups. Mean time for occurrence of TB was 18.4 ± 10.6 months after renal transplantation. Rituximab use was not significantly associated with TB or any other infection. Higher number of rejection episodes (60% vs. 32.72%, p =.029) was the only factor associated with greater incidence of TB. However, no specific type of rejection was associated with TB. Use of plasmapheresis in post‐transplant period for treatment of humoral rejections was associated with significantly higher incidence of TB (33.33% vs. 13.41%, p =.031); however, when pre‐transplant plasmapheresis was also considered, there was no significant difference. The choice of induction agent was not associated with higher incidence of TB. Conclusion: Use of rituximab is not associated with higher incidence of TB when compared to other immunosuppressive agents. Routine screening and prophylaxis may not be advisable, especially in a country like India with high prevalence of TB, as it will further delay transplantation and may adversely affect the outcome of the patients. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
8. Aetiology, management, and outcome of lower respiratory tract infection in renal allograft recipients – A report from a tropical country.
- Author
-
Jain, Sakshi, Bhadauria, Dharmendra, Prasad, Raghunandan, Gurjar, Mohan, Yaccha, Monika, Shanmugham, Sabrinath, Kaul, Anupma, Rungmei Marak, S, Nath, Alok, and Prasad, Narayan
- Subjects
RESPIRATORY infections ,ETIOLOGY of diseases ,ASPERGILLOSIS ,SEPTIC shock ,HOMOGRAFTS - Abstract
Introduction: Lower respiratory tract infections (LRTIs) among renal transplant recipients (RTRs) are a significant cause of morbidity and mortality. This study aimed to analyse the aetiology, outcome, and risk factors associated with mortality. Methods: We analysed baseline transplant characteristics, symptoms, hospital course, laboratory, serological and microbial results, and their association with the outcome of all RTRs between January 2011 and December 2019. Results: A total of 206 LRTI patients out of 1051 RTRs were analysed. The incidence proportion was nearly 22 episodes per 1000 patients per year. The mean age was 39.3 years, with male predominance. Bacterial was the most common aetiology (53%), and staphylococcus was the most common species. Among the fungal causes (14%), 68% had aspergillus infection. More than one-third RTRs died during the hospital course mainly because of bacterial causes (42.6%). The aspergillus infection was the most common fungus associated with 50% mortality. On multi-variate analysis, sepsis, septic shock, and the need for mechanical ventilation independently predicted mortality. Conclusion: Bacterial aetiology was the most common cause; though the fungal aetiology was seen less, it was associated with higher mortality. Mortality in RTR with LRTI was associated with sepsis, septic shock, and the need for mechanical ventilation. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
9. Antibody Response to ChAdOx1 nCoV-19 (AZD1222) Vaccine in Kidney Transplant Recipients.
- Author
-
Bhadauria, Dharmendra S., Katiyar, Harshita, Goel, Amit, Tiwari, Prachi, Kishore, Ravi V. Krishna, Aggarwal, Amita, Verma, Alka, Khetan, Dheeraj, Kaul, Anupma, Yachha, Monika, Behera, Manas Ranjan, Yadav, Brijesh, and Prasad, Narayan
- Subjects
KIDNEY transplantation ,ANTIBODY formation ,COVID-19 vaccines ,COVID-19 ,BINDING site assay - Abstract
Kidney transplant recipients (KTRs) are at a much higher risk of complications and death following COVID-19 and are poor vaccine responders. The data are limited on the immune response to Covishield
® in KTRs. We prospectively recruited a cohort of 67 KTRs aged >18 between April 2021 and December 2021. Each participant was given two intramuscular doses of Covishield® , each of 0.5 mL, at an interval of 12 weeks. A blood specimen of 5.0 mL was collected from each participant at two points within a few days before administering the first dose of the vaccine and at any time between 4–12 weeks after administering the second dose. The sera were tested for anti-RBD antibody (ARAb) titre and neutralising antibody (NAb). An ACE2 competition assay was used as a proxy for virus neutralization. According to the prior COVID-19 infection, participants were grouped as (i) group A: prior symptomatic COVID-19 infection, (ii) group B: prior asymptomatic COVID-19 infection as evidenced by detectable ARAb in the prevaccination specimen, (iii) Group C: no prior infection with COVID-19, (iv) group D: Unclassified, i.e., participants had no symptoms suggestive of COVID-19, but their prevaccination specimen was not available for ARAb testing before vaccination. Fifty of sixty-seven participants (74.6%) provided paired specimens (group A 14, group B 27, and group C 9) and 17 participants (25.4%) provided only postvaccination specimens (group D). In the overall cohort (n = 67), 91% and 77.6% of participants developed ARAb and NAb, respectively. Their ARAb titre and NAb proportion were 2927 (520–7124) U/mL and 87.9 (24.4–93.2) %, respectively. Their median ARAb titre increased 65.6 folds, from 38.2 U/mL to 3137 U/mL. Similarly, the proportion of participants with NAb increased from 56% to 86%, and the NAb proportion raised 2.7 folds, from 23% to 91%. A comparison of vaccine response between the study groups showed that all those with or without prior COVID-19 infection showed a significant rise in ARAb titre (p < 0.05) and NAb proportion (p < 0.05) after the two doses of vaccine administration. The median value of folds rise in anti-RBD and NAb between groups A and B were comparable. Hence, ARAb is present in more than 3/4th of KTRs before the ChAdOx1 vaccine in India. The titer of ARAb and the proportion of NAb significantly increased after the two doses of the ChAdOx1 vaccine in KTRs. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
10. Impact of Kidney Donation on Pregnancy Outcomes: A Retrospective Analysis.
- Author
-
Kaul, Anupma, Bhaduaria, Dharmendra, Yachha, Monika, Behera, Manas Ranjan, Kushwaha, Ravi, Prasad, Narayan, Patel, Manas Ranjan, and Srivastava, Aneesh
- Subjects
MULTIVARIATE analysis ,KIDNEY transplantation ,RETROSPECTIVE studies ,PREGNANCY outcomes ,RISK assessment ,PRE-tests & post-tests ,QUESTIONNAIRES ,DESCRIPTIVE statistics ,ORGAN donors - Abstract
Introduction: Recent data suggest a risk of gestational hypertension, proteinuria and pre-eclampsia among pregnancies after kidney donation. Methods: This retrospective study among females who donated kidneys (1997--2017) at a tertiary renal transplant center in Northern India assessed the maternal and fetal outcomes of their pregnancy. Data of participants were collected using pre-tested semi structured questionnaire. Results: In total, 925 female kidney donors (1332 pregnancies) in the pre-donation group and 45 females (48 pregnancies) in the post donation period were included. The mean age of first pregnancy, weight (kg) gain, proportion of history of pre-natal check-up, institutional delivery, and history of unrelated donation was statically significant among the post-donation group. The proportion of pre-eclampsia, gestational hypertension, gestational diabetes, and post-partum hemorrhage was insignificantly higher among the post-donation group with higher preterm birth with low-birth-weight babies. Proteinuria (P < 0.05) was significantly higher among post donation pregnancies. In multivariate analysis, cesarean delivery and low birth weight (<2500 g) were common among the post-donation pregnancy group. Conclusions: The study demonstrated no significant risk to maternal outcomes butan increased risk to fetal outcomes in terms of prematurity and low birth weight among the post-donation pregnancy group. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
11. Desmopressin Acetate Before Percutaneous Ultrasound-Guided Kidney Biopsy in Patients with Renal Failure -- Is it Really Beneficial?
- Author
-
Jose, Leena, Kaul, Anupma, Bhadauria, Dharmendra, Kushwaha, Ravi, Nandan, Raghu, Lal, Hira, Prasad, Narayan, Behera, Manas Ranjan, and Patel, Manas Ranjan
- Subjects
PREVENTION of surgical complications ,HEMORRHAGE prevention ,GLOMERULAR filtration rate ,BIOPSY ,SCIENTIFIC observation ,KIDNEY failure ,DESMOPRESSIN ,RETROSPECTIVE studies ,SURGICAL complications ,TREATMENT effectiveness - Abstract
Introduction: The most common complication of percutaneous renal biopsy is bleeding, which can be seen in up to one-third of cases. The aim of this study was to evaluate the effect of prebiopsy administration of intranasal desmopressin acetate in reducing the incidence of biopsy-related bleeding complications in patients with significant renal dysfunction who underwent renal biopsy. Methods: This was a retrospective, observational study of percutaneous native renal biopsies performed at our center from July 2014 to June 2018. Bleeding complication rates of patients with renal failure (estimated glomerular filtration rate [eGFR] <30 mL/minute/1.73 m2 ) who received desmopressin and those who did not receive desmopressin were compared. Results: Desmopressin administration before renal biopsy in patients with eGFR <30 mL/minute/1.73 m2 was associated with a significant reduction of bleeding complications (major and minor together; P = 0.025) and no significant reduction in major complications (P = 0.616) or intervention rates (P = 0.251) when compared with a group that did not receive desmopressin. Conclusions: While prebiopsy intranasal desmopressin use was associated with a significant reduction of overall bleeding complications including major and minor complications, there was no reduction in the rate of other major complications and interventions. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
12. Delayed onset bleed after percutaneous kidney biopsy: is it the same as early bleed?
- Author
-
Bhadauria, Dharmendra, Jose, Leena, Kushwaha, Ravi, Kaul, Anupma, Nandan, Raghu, Singh, Vivek, and Prasad, Narayan
- Subjects
RENAL biopsy ,HEALTH facilities ,DIASTOLIC blood pressure ,SYSTOLIC blood pressure ,TERTIARY care ,SURGICAL complication risk factors ,HEMORRHAGE risk factors ,KIDNEYS ,BIOPSY ,HEMOGLOBINS ,BLOOD transfusion ,SURGICAL complications ,RETROSPECTIVE studies ,KIDNEY transplantation ,TREATMENT effectiveness ,DESCRIPTIVE statistics ,THERAPEUTIC complications ,HEMORRHAGE - Abstract
Background: While the majority of bleeding complications after a percutaneous kidney biopsy (PKB) occur early (≤24 h), delayed onset bleeding complications (>24 h) have been rarely reported and can be catastrophic for the patient. Purpose: To describe the incidence, risk factors, and outcomes of delayed bleeding complications after PKB. Material and Methods: We retrospectively studied native and graft kidney biopsies in patients who developed delayed bleeding complications (>24 h) after the biopsy performed in the Department of Nephrology and Renal Transplantation of a tertiary care medical institution in north India between January 2014 to December 2018. Results: Of the 4912 renal biopsies reviewed, 20 patients (16 men, 4 women; 0.40%) had a delayed biopsy bleeding complication. Of these patients, 95% had major bleeding complications requiring blood transfusions and 85% needed intervention like gelfoam/coil embolization. Despite intervention, one patient (5%) had mortality due to complications of bleeding and sepsis. When compared to a control group of patients with early biopsy bleed, patients with the delayed biopsy bleed had similar demographic and clinical profiles except for higher pre-biopsy hemoglobin and lower systolic and diastolic blood pressure. Conclusion: A post-PKB delayed onset bleed is not uncommon, and the vast majority of these patients had major bleeding complications requiring blood transfusions and/or intervention like embolization. They had a similar demographic and clinical profile presentation as early bleed patients. Meticulous outpatient monitoring and patient education after discharge may be useful to detect this complication promptly and to intervene early to have good patient outcome. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
13. Efficacy and Safety of Bortezomib in the Treatment of Active Antibody-Mediated Rejection in Adult Kidney-Transplant Recipients: A Single-Center Retrospective Study.
- Author
-
Bhadauria, Dharmendra, Kumar, Sai, Yachha, Monika, Kaul, Anupma, Patel, Manas Ranjan, Kushwaha, Ravi Shankar, Behera, Manas R, and Prasad, Narayan
- Published
- 2022
- Full Text
- View/download PDF
14. Acute hepatitis C treatment in advanced renal failure using 8 weeks of pan-genotypic daclatasvir and reduced-dose sofosbuvir.
- Author
-
Goel, Amit, Bhadauria, Dharmendra S, Kaul, Anupma, Verma, Abhai, Tiwari, Prachi, Rungta, Sumit, Rai, Praveer, Gupta, Amit, and Aggarwal, Rakesh
- Subjects
HEPATITIS C treatment ,SOFOSBUVIR ,CHRONIC kidney failure ,HEPATITIS C virus ,HEMODIALYSIS - Abstract
Background Sofosbuvir is not recommended in persons with estimated glomerular filtration rate (eGFR) <30 mL/min. We report the results of treatment with an off-label 8-week regimen of daclatasvir and half-dose sofosbuvir in patients with acute infection with hepatitis C virus (HCV) and eGFR <30 mL/min. Methods Clinic records were searched to identify treatment-naïve, noncirrhotic adults with acute hepatitis C (HCV viremia and a ≥10-fold elevation of serum alanine aminotransferase activity) and eGFR <30 mL/min, who had been treated with a sofosbuvir-based regimen. Treatment response was assessed using serum HCV RNA testing at 4 weeks of treatment, end of the 8-week treatment and 12 weeks after stopping treatment. Results Of the 31 patients with acute hepatitis C, 27 [median age (range): 36 (18–74) years; 20 (74%) male] were started on treatment with 200 mg sofosbuvir and 60 mg daclatasvir daily for 8 weeks, irrespective of HCV genotype. All the 27 completed the planned 8-week treatment. One patient died 10 weeks after completing the treatment of an unrelated cause. All the 27 patients had undetectable HCV RNA after 4 weeks of and at the end of treatment. At 12 weeks after completion of treatment, only one tested HCV RNA positive and 25 were negative, with sustained virological response rate of 25/27 (92.6%) and 25/26 (96.2%) on intention-to-treat and per-protocol basis, respectively. Conclusion Eight-week course of daclatasvir and half-dose sofosbuvir is effective for acute hepatitis C in patients with eGFR <30 mL/min and could be a useful alternative to costly, kidney-safe anti-HCV oral drugs in resource-constrained settings. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
15. Co-existence of acute pancreatitis with hemolytic uremic syndrome: "The dilemma of a rare organ cross-talk".
- Author
-
Sharma, Harshita, Bhadauria, Dharmendra, Goel, Amit, Yaccha, Monika, Gurjar, Mohan, Kaul, Anupma, Veeranki, Vamsidhar, Shamungham, Sabrinath, Jain, Manoj, Mohindra, Sameer, and Prasad, Narayan
- Published
- 2022
- Full Text
- View/download PDF
16. Aftermath of fortnightly universal testing for severe acute respiratory corona virus‐2 infection in maintenance hemodialysis patients.
- Author
-
Patel, Manas R., Kushwaha, Ravi S., Behera, Manas, Bhadauria, Dharmendra S., Yachha, Monika, Kaul, Anupma, and Prasad, Narayan
- Subjects
HEMODIALYSIS patients ,REVERSE transcriptase polymerase chain reaction ,INFECTION ,SARS-CoV-2 - Abstract
Introduction: Asymptomatic maintenance hemodialysis patients with acute respiratory corona virus‐2 (SARS‐COV‐2) are missed with pre‐dialysis screening without testing. The possible ideal strategy of testing each patient before each shift with reverse transcription polymerase chain reaction (RT‐PCR) is not feasible. We aimed to study the effectiveness of fortnightly screening with RT‐PCR for SARS‐CoV‐2 in curbing transmission. Methods: Between July 1, 2020 and September 30, 2020, all 273 patients receiving hemodialysis were subjected to fortnightly testing for SARS‐Cov‐2 in the unit to detect asymptomatic patients. The cost and effectiveness of universal testing in preventing transmission were analyzed using susceptible‐infectious‐removed (SIR) modeling assuming R0 of 2.2. Results: Of 273 MHD patients, 55 (20.1%) found infected with SARS‐CoV‐2 over 3 months. Six (10.9%) were symptomatic, and 49 (89.1%) asymptomatic at the time of testing. Six (10.9%) asymptomatic patients develop symptoms later, and 43 (78.2%) remained asymptomatic. A total of seven (6.1%) HCWs also tested positive for the virus. Fortnightly universal testing is cost‐effective, and SIR modeling proved effective in preventing person‐to‐person transmission. Conclusions: Repeated universal testing in maintenance hemodialysis patients detected 89% of asymptomatic SARS‐CoV‐2 patients over 3 months and appeared to be an effective strategy to prevent person‐to‐person transmission in the dialysis unit. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
17. Etiological Spectrum and Clinical Features in 215 Patients of Crescentic Glomerulonephritis: Is it Different in India?
- Author
-
Gupta, Anubha, Agrawal, Vinita, Kaul, Anupma, Verma, Ritu, Jain, Manoj, Prasad, Narayan, and Pandey, Rakesh
- Subjects
BIOPSY ,ANTINEUTROPHIL cytoplasmic antibodies ,COMPARATIVE studies ,PROTEINURIA ,SURVIVAL analysis (Biometry) ,DESCRIPTIVE statistics ,GLOMERULONEPHRITIS ,CREATININE ,NECROSIS ,VASCULITIS ,FOCAL segmental glomerulosclerosis ,DISEASE complications - Abstract
Introduction: Crescentic glomerulonephritis (CrGN) characterized by the presence of crescents in most (≥50%) glomeruli on renal histology clinically presents as rapidly progressive renal failure. It can occur due to diverse etiologies with varying course and renal outcomes. We studied the prognostic significance of its classification as pauci-immune, anti-GBM, and immune-complex mediated CrGN. Materials and Methods: Renal biopsies diagnosed as CrGN over 9 years were included. Clinical, biochemical, serological, and histological features of various classes of CrGN were correlated with renal outcome. Results: 215 biopsies were diagnosed as CrGN during this period. A majority (63%) were immune-complex mediated while 32% were pauci-immune, followed by anti-GBM disease (5%). 85.5% of pauci-immune CrGN were ANCA associated. The levels of proteinuria and serum creatinine were significantly higher in anti-GBM CrGN as compared to the other two classes. The various histological features including Bowman's capsule rupture, peri-glomerular granulomatous reaction, fibrinoid necrosis, and vasculitis were more common in anti-GBM disease and pauci-immune CrGN. The median renal survival was 6.3, 5.3, 2.1 months in immune-complex mediated, pauci-immune, and anti-GBM CrGN, respectively. Conclusion: Immune-complex mediated is the commonest etiology of CrGN in India. Anti-GBM disease has the worst prognosis followed by pauci-immune and immune-complex mediated CrGN. Raised serum creatinine levels (>5mg%) and the degree of glomerulosclerosis at diagnosis were predictors of poor renal survival. High index of suspicion and prompt diagnosis can improve the outcome in these patients. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
18. Determination of split renal function in voluntary renal donors by multidetector computed tomography and nuclear renography: How well do they correlate?
- Author
-
Lai, Hira, Singh, Anuradha, Prasad, Raghunandan, Yadav, Priyank, Akhtar, Javed, Barai, Sukanta, Mishra, Prabhakar, Bhadauria, Dharmendra, Kaul, Anupma, Prasad, Narayan, and Verma, Pragati
- Subjects
KIDNEY physiology ,RESEARCH ,STATISTICS ,STATISTICAL significance ,MULTIDETECTOR computed tomography ,ONE-way analysis of variance ,KIDNEY transplantation ,REGRESSION analysis ,RADIONUCLIDE imaging ,MATHEMATICAL variables ,T-test (Statistics) ,DESCRIPTIVE statistics ,CHI-squared test ,STATISTICAL correlation ,DATA analysis ,DATA analysis software ,LONGITUDINAL method - Abstract
Background: The use of computed tomography (CT) for estimation of split renal function (SRF) has been reported previously. However, most of these studies have small samples, and many do not account for the renal attenuation at CT. Objective: The aim of this study was to compare multidetector computed tomography (MDCT) volumetry-attenuation-based SRF with that obtained via Tc99m-diethylenetriaminepentaacetic acid (DTPA) renal scintigraphy in voluntary renal donors. Methods: Between January 2017 and January 2020, 526 voluntary renal donors were enrolled prospectively. All donors underwent contrast CT and DTPA scan before surgery. The semiautomatic region of interest (ROI) tool was applied slice by slice on axial CT images acquired in the arterial phase. The renal contour was drawn semiautomatically with mouse clicks around the renal parenchyma, and the renal volume was ascertained. Using renal volume and attenuation, SRF was determined and compared with results obtained at DTPA imaging. Results: The mean age was 44.91 ± 10.97 years (mean ± s.d.). There was no significant difference in SRF based on DTPA and MDCT volumetry for the left kidney (49.18% ± 3.40% vs. 49.15% ± 3.38%, p = 0.540) and for the right kidney (50.82% ± 3.40% vs. 50.86% ± 3.39%, p = 0.358). A very good correlation was observed between the two methods for the left kidney (r = 0.953, p = 0.000) and the right kidney (r = 0.955, p = 0.000). On simple linear regression analysis, 90.8% of DTPA SRF values for the left kidney and 91.3% of DTPA SRF values for the right kidney could be predicted correctly using the corresponding MDCT SRF values. Conclusion: MDCT volumetry-attenuation-derived estimation of SRF for living renal donors could be an alternative to renal scintigraphy-based SRF estimation. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
19. Daclatasvir and reduced‐dose sofosbuvir: An effective and pangenotypic treatment for hepatitis C in patients with estimated glomerular filtration rate <30 mL/min.
- Author
-
Goel, Amit, Bhadauria, Dharmendra S, Kaul, Anupma, Verma, Prashant, Mehrotra, Mayank, Gupta, Amit, Sharma, Raj K, Rai, Praveer, and Aggarwal, Rakesh
- Subjects
GLOMERULAR filtration rate ,HEPATITIS C treatment - Abstract
Aim: Sofosbuvir is a key agent for HCV treatment. It is not recommended for patients with chronic kidney disease (CKD) and estimated glomerular filtration rate (eGFR) <30 mL/min. We report real‐life experience of treating a cohort of CKD patients with eGFR <30 mL/min using daclatasvir and half‐daily dose of sofosbuvir. Methods: Adults patients who (i) had eGFR<30 mL/min and detectable HCV RNA and (ii) were treated with interferon and ribavirin free, DAA based regimens were included. All patients were treated with daily doses of daclatasvir 60 mg and sofosbuvir 200 mg. The planned duration of treatment was 12 weeks, except for 24 weeks in those with either clinical evidence of cirrhosis or on immunosuppressive drugs. The end‐points of the study were: (i) 12 weeks of follow‐up after treatment completion, (ii) treatment discontinuation, or (iii) death or loss to follow‐up. Results: Thirty‐six (88%) among 41 included patients (median [range] age: 48 [19–75] years; 25 [61%] male; genotype 1/3/4 were 17/ 22/2; cirrhosis 5) completed the treatment, two discontinued and three died during treatment. On an intention‐to‐treat basis, HCV RNA were undetectable at 4 weeks of treatment, treatment completion and after 12 weeks of follow‐up in 40/41 (97.6%), 37/41 (90.2%) and 37/41 (90.2%), respectively. None of the patients had a relapse. Conclusions: Daclatasvir and half‐daily dose of sofosbuvir was effective against genotype 1 and 3 HCV infection in patients with eGFR <30 mL/min. This combination could be a pangenotypic treatment option for such patients. Summary at a Glance: This is a real‐world report on the use of DAAs for pan‐genotypic HCV infection in patients with significant renal impairment in a resource constrained setting. It provides useful additional data for clinicians outside of clinical trial reports. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
20. Role of Blood Oxygen Level-dependent MRI in Differentiation of Acute Renal Allograft Dysfunction.
- Author
-
Lal, Hira, Mohamed, Ezaz, Soni, Neelam, Yadav, Priyank, Jain, Manoj, Bhadauria, Dharmendra, Kaul, Anupma, Prasad, Narayan, Gupta, Amit, and Sharma, R. K.
- Subjects
ACUTE kidney tubular necrosis ,REACTIVE oxygen species ,BIOPSY ,BLOOD gases analysis ,GRAFT rejection ,HOMOGRAFTS ,KIDNEY transplantation ,LONGITUDINAL method ,MAGNETIC resonance imaging ,ORGAN donors ,OXYGEN in the body ,POSTOPERATIVE period ,STATISTICS ,TRANSPLANTATION of organs, tissues, etc. ,DATA analysis ,MULTIPLE regression analysis ,TREATMENT effectiveness ,ONE-way analysis of variance ,EVALUATION ,DISEASE risk factors - Abstract
Early graft dysfunction after renal transplantation manifests as acute rejection (AR) or acute tubular necrosis (ATN). Blood oxygen level-dependent (BOLD) magnetic resonance (MR) imaging is a noninvasive method of assessing tissue oxygenation, which may be useful for predicting acute allograft dysfunction. This was a prospective study involving 40 patients scheduled for renal transplantation from August 2012 to August 2014. In addition, 15 healthy donors were also enrolled in this study. All recipients underwent BOLD MR imaging (MRI) and R2* mapping 10-20 days after transplant, and additionally within 48 h of biopsy if there was any evidence of graft dysfunction. The healthy donors underwent BOLD MRI 1-2 days before surgery. The biopsies were grouped into AR, ATN, and no evidence of AR or ATN. The mean medullary R2*, cortical R2*, corticomedullary gradient, and medullary: cortical R2* ratio were compared between groups using one-way analysis of variance. Spearman's correlation and multinomial linear regression were applied to determine the influence factors of R2* value. Overall, nine patients had graft dysfunction. Six were reported as AR, two as ATN, and one as no evidence of ATN or rejection. The mean medullary and cortical R2* were significantly higher in ATN group compared with AR and normal group, whereas the mean medullary and cortical R2* of AR group were significantly lower than normal group. The corticomedullary gradient of AR group was significantly lower compared with ATN and normal group. Medullary R2*:cortical R2* ratio was significantly lower in AR group compared with normal group. No significant difference was noted between the 15 donors and patients with normal graft function. R2* values on BOLD MRI are significantly decreased in AR allografts and increased in an early stage of ATN allografts, suggesting that BOLD MRI can become a valuable tool for discriminating between AR and ATN. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
21. Efficacy and safety of sofosbuvir-based antiviral therapy to treat hepatitis C virus infection after kidney transplantation.
- Author
-
Reddy, Suresh, Sharma, Raj Kumar, Mehrotra, Sonia, Prasad, Narayan, Gupta, Amit, Kaul, Anupma, and Bhadauria, Dharmendra Singh
- Abstract
Background The objectives of this pilot study were to assess the efficacy and safety of an interferon-free sofosbuvir and ribavirin combination regimen to treat chronic hepatitis C virus (HCV) infection in kidney transplant recipients and to study the impact of sofosbuvir on calcineurin inhibitor (CNI) drug levels. Methods A total of 10 kidney transplant recipients with chronic HCV infection were included in the study. All received sofosbuvir and ribavirin combination therapy. The virological response to therapy and the adverse effects of the drugs were studied. The area under the curve (AUC) and pharmacokinetic data of levels of CNI were compared while the patients were receiving sofosbuvir and ribavirin drugs and when they were no longer on these drugs. Results In all, 9 of 10 patients (90%) achieved rapid virological response (RVR) with undetectable HCV RNA at 4 weeks and the remaining patient achieved undetectable HCV RNA at 8 weeks. A sustained virological response was seen at 3, 6 and 12 months and was maintained in all 10 patients (100%). The important aspect of the study is the effect of treatment with the sofosbuvir–ribavirin combination regimen on the CNI AUC levels, which resulted in a reduction in the CNI AUC. While used as part of triple-drug immunosuppression, no change in the dose of CNI (tacrolimus and cyclosporine) was required based on measurement of C0 levels. Conclusions The sofosbuvir and ribavirin combination therapy is effective and safe to treat HCV infection in the post-renal transplant setting. There is a need for close CNI level monitoring while these patients are on sofosbuvir therapy. With therapy and viral clearance, there could be reduction in CNI levels due to increased clearance of CNI drugs, which is shown by the AUC measurements. This could be important for patients at high risk for rejection. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
22. Idiopathic membranous nephropathy in patients with diabetes mellitus: a diagnostic and therapeutic quandary!
- Author
-
Bhadauria, Dharmendra, Chellappan, Anand, Kaul, Anupma, Etta, Praveen, Badri, Vinay, Sharma, Raj Kumar, Prasad, Narayan, Gupta, Amit, and Jain, Manoj
- Subjects
KIDNEY disease treatments ,KIDNEY disease diagnosis ,DIABETES complications - Abstract
Background: Proteinuria and renal dysfunction is common in diabetic patients andmay occur due to variety of causes. Nondiabetic renal diseases (NDRD) account for 30% of the renal biopsies, and idiopathicmembranous nephropathy (iMN) is a common non diabetic glomerular disease that can exist alone or in combination with diabetic nephropathy (DN). Immunosuppressants used in iMN may be associated with complications of worsening glycemic control and recurrent infections. There is a paucity of literature on the clinical course, outcomes and treatment adverse effects of patients with iMN and diabetes. Methods: We retrospectively analyzed the data of all diabetics, evaluated for NDRD and found to have iMN, between January 2000 and June 2015 in our institute. Results: A total of 134 patients with diabetes were biopsied for NDRD and 16 patients had iMN. Mean 6 standard deviation age was 54611.77 years and the median duration of diabetes was 9.4 years. Twelve patients had isolated iMN and four patients had iMN coexisting with DN. Response rates of 18%, 35.71% and 63.63% were seen with Modified Ponticelli (MP) regimen, tacrolimus and mycophenolate mofetil (MMF), respectively. Five patients developed treatment-related adverse effects significant enough to necessitate a treatment change. Worsening glycemic control was the most common side effect. Adverse effects were less with the MMF compared with the MP regimen and tacrolimus. Conclusion: Patients with iMN coexisting with diabetes exhibit a poor response to the MP regimen. Treatment-related toxicity is less common with MMF in comparison with the MP regimen and tacrolimus-based regimen. An almost similar response was noted with MMF and tacrolimus-based regimen but there was more withdrawal from treatment due to toxicities observed in the latter. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
23. Safety and effectiveness of response-guided therapy using pegylated interferon and ribavirin for chronic hepatitis C virus infection in patients on maintenance dialysis.
- Author
-
Goel, Amit, Bhadauria, Dharmendra Singh, Kaul, Anupma, Prasad, Narayan, Gupta, Amit, Sharma, Raj Kumar, Rai, Praveer, and Aggarwal, Rakesh
- Subjects
INTERFERONS ,RIBAVIRIN ,CHRONIC hepatitis C ,PATIENT safety ,TREATMENT effectiveness ,CHRONIC kidney failure ,PATIENTS ,THERAPEUTICS - Abstract
Aim Treatment of hepatitis C virus (HCV) infection in patients with end-stage renal disease (ESRD) is difficult. Addition of ribavirin to pegylated-interferon (Peg-IFN) may help to improve the treatment response. Further, treatment duration could be shortened using a response-guided treatment (RGT) approach. Methods We retrospectively reviewed records of treatment-naïve adult patients with ESRD and chronic HCV infection who had been treated with Peg-IFN and low-dose ribavirin using a RGT approach. Rapid responders (undetectable HCV-RNA at 4 weeks) received treatment for 12 weeks, and slow responders (HCV-RNA detectable at 4 weeks, but undetectable or with >2.0 log
10 reduction at week 12) for 24 (genotype 3; GT3) or 48 (genotype 1; GT1) weeks. In those without such reduction (null responders), treatment was discontinued. Results Of 26 non-cirrhotic patients (GT1 15, GT3 11) treated, four (15%; GT1 3, GT3 1) were null responders. Twenty-two (85%) patients had either rapid ( n = 14 (54%); GT1 10, GT3 4) or slow response ( n = 8 (31%); GT1 2, GT3 6). Of them, 21 patients had undetectable RNA at the end of treatment; one could not complete the treatment and was lost thereafter. There were no deaths during treatment. Three patients relapsed and three others died in 6 months after stopping treatment. Overall, 15/26 (58%) patients attained SVR24. Fourteen patients underwent transplantation beginning one month after treatment completion, and all were relapse-free after 17 (14-24) months of follow-up. Conclusion RGT using Peg-IFN and ribavirin was effective in ESRD patients on maintenance dialysis. Renal transplant was safely done within one month of completing such treatment. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
24. Luminex Solid-Phase Crossmatch for De Novo Donor-Specific Antibodies in Living-Donor Related Transplants.
- Author
-
Mehrotra, Sonia, Sharma, Raj Kumar, Mayya, Mahabaleshwar, Gupta, Amit, Prasad, Narayan, Kaul, Anupma, and Bhadauria, Dharmendra Singh
- Published
- 2017
- Full Text
- View/download PDF
25. Experience with direct acting anti-viral agents for treating hepatitis C virus infection in renal transplant recipients.
- Author
-
Goel, Amit, Bhadauria, Dharmendra, Kaul, Anupma, Prasad, Narayan, Gupta, Amit, Sharma, Raj, Rai, Praveer, and Aggarwal, Rakesh
- Abstract
In recent past, direct-acting anti-viral drugs (DAAs) have become the standard of care for the treatment of hepatitis C virus (HCV) infection. However, the experience with the use of these drugs in Indian renal transplant recipients is limited. We retrospectively reviewed our experience with DAA-based treatment for HCV infection in such patients. Between April 2015 and December 2016, six adults (median age 41 [range 34-52] years, male 5; GT1 2, GT3 3, and GT4 1; including three with prior failed interferon-based treatment) had received genotype-guided, DAA-based anti-HCV treatment 1 to 158 (median 15) months after renal transplantation. Of them, four completed the planned 24-week treatment without any significant adverse event. One of them had increase in serum creatinine after 16 weeks of treatment with sofosbuvir and daclatasvir, with acute interstitial nephritis on kidney biopsy; his renal function improved on stopping the drugs. The other patient had preexisting mild renal dysfunction, which worsened after 8 weeks of sofosbuvir-ledipasvir treatment; this did not reverse on stopping treatment. All the six patients achieved undetectable HCV RNA after 4 weeks of treatment and also achieved sustained virologic response, i.e. lack of detectable HCV RNA in serum 12 weeks after stopping treatment. Overall, DAA-based treatment was effective in treating HCV infection in our renal transplant recipients; however, caution and monitoring of renal function during such treatment is advisable in patients who have additional factors that predispose to renal injury. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
26. Paraneoplastic nephrotic syndrome in a patient with planum sphenoidale meningioma.
- Author
-
Sardhara, Jayesh, Shukla, Mukesh, Jamdar, Janmejay, Jaiswal, Awadhesh, Jaiswal, Sushila, Kaul, Anupma, Bhaisora, Kamlesh, Das, Kuntal, Mehrotra, Anant, and Behari, Sanjay
- Subjects
PARANEOPLASTIC syndromes ,MENINGIOMA ,EDEMA ,ASCITES ,BLOOD diseases ,PATIENTS - Abstract
A 60-year-old homemaker presenting with pedal edema and ascites was found to have a planum sphenoidale meningioma concurrently with nephrotic syndrome. On renal biopsy, the patient was found to have membranous glomerulonephritis. There was complete remission of nephropathy after excision of the meningioma. Nephrotic syndrome has been commonly found in association with malignancies and blood disorders but the association with a meningioma is extremely rare, and only one case has been previously reported as per our knowledge. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
27. Childhood lupus with microangiopathic antiphospholipid syndrome and pulmonary hemorrhage.
- Author
-
Bhadauria, Dharmendra, Etta, Praveen, Kaul, Anupma, and Prasad, Narayan
- Subjects
PEDIATRICS ,LUPUS erythematosus ,CUTANEOUS tuberculosis ,ANTIPHOSPHOLIPID syndrome ,AUTOIMMUNE diseases - Abstract
Background: Concurrent thrombotic and hemorrhagic manifestations are uncommon in patients with Antiphospholipid Syndrome. Case characteristics: A 10-year-old girl with fever, edema, rash and joint pains, who later developed deep venous thrombosis (DVT), stroke, thrombotic microangiopathic hemolytic anemia and pulmonary hemorrhage. Investigations confirmed Antiphospholipid syndrome associated with systemic lupus erythematosus. Outcome: She went into complete remission with intravenous immunoglobulins, plasmapheresis, immunosuppression and anticoagulation. Message: Thrombotic microangiopathic hemolytic anemia and anti-phospholipid syndrome can be the presenting manifestations of systemic lupus erythematosus.. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
28. The "dilemma of double lifelines": central venous catheter co-existence with transvenous cardiac pacemaker.
- Author
-
Bhadauria, Dharmendra, Chellappan, Anand, Gurjar, Mohan, Kaul, Anupma, Sharma, Raj Kumar, and Prasad, Narayan
- Published
- 2017
- Full Text
- View/download PDF
29. Renal allograft dysfunction secondary to recurrent perigraft lymphatic collection managed with percutaneous sclerotherapy with povidone iodine.
- Author
-
Lal, Hira, Gupta, Bharat, Asmita, null, Yadav, Priyank, Vishwakarma, Kavita, Kaul, Anupma, and Sharma, R.K.
- Published
- 2017
- Full Text
- View/download PDF
30. Chickenpox infection after renal transplantation.
- Author
-
Kaul, Anupma, Sharma, Raj K., Bhadhuria, Dharmendra, Gupta, Amit, and Prasad, Narayan
- Subjects
CHICKENPOX ,KIDNEY transplantation ,IMMUNOCOMPROMISED patients ,JUVENILE diseases ,FOLLOW-up studies (Medicine) ,HEALTH outcome assessment ,ACYCLOVIR - Abstract
Background. Chicken pox, although a common infection among children, is rare in immunocompromised patients, particularly renal transplant recipients, and carries a very high incidence of morbidity and mortality There is little data on chickenpox in adult renal transplant recipients, although reports have suggested that it may follow a virulent course requiring frequent hospitalization, and in severe cases can cause death. Aims. To evaluate the incidence, severity and complications of a varicella/chickenpox infection in renal transplant recipients over 10 years follow-up. Results. An incidence of 1.48% of our patients were diagnosed with varicella infection during this 10-year period from June 2000 to June 2010 in our live-related renal transplant program, with a median patient age of 39 years (range 21–54 years). Graft dysfunction was observed among five patients following the infection, two of whom became dialysis-dependent. The other three had mild graft dysfunction from which they subsequently recovered, suggesting that infection was responsible for graft dysfunction. None of them developed rejection following exposure or with modification of immunosuppression. All of our patients required admission with 47.8% presenting with various presentations, with orchitis, pancreatitis, encephalitis and gastritis each affecting 8.6% of the patients. All patients were managed with intravenous acyclovir for 2 weeks followed by oral acyclovir for 3 months. The infection was associated with an increased mortality of 13.4% due to superadded infections and central nervous system involvement in one patient with fatal bilateral pneumonia. Conclusions. This infection, which is a benign disease with a largely stable course among the general population, can have severe outcomes for immunocompromised patients, accounting for almost 90% with significant morbidity and mortality in the 8.6% of infected patients, thus highlighting the importance of pre-transplant vaccination in this subgroup of the population. [ABSTRACT FROM PUBLISHER]
- Published
- 2012
31. Chickenpox infection after renal transplantation.
- Author
-
Kaul, Anupma, Sharma, Raj K., Bhadhuria, Dharmendra, Gupta, Amit, and Prasad, Narayan
- Subjects
CHICKENPOX ,KIDNEY transplantation ,IMMUNOCOMPROMISED patients ,IMMUNOSUPPRESSION ,ACYCLOVIR ,PNEUMONIA - Abstract
Background. Chicken pox, although a common infection among children, is rare in immunocompromised patients, particularly renal transplant recipients, and carries a very high incidence of morbidity and mortality There is little data on chickenpox in adult renal transplant recipients, although reports have suggested that it may follow a virulent course requiring frequent hospitalization, and in severe cases can cause death. Aims. To evaluate the incidence, severity and complications of a varicella/chickenpox infection in renal transplant recipients over 10 years follow-up. Results. An incidence of 1.48% of our patients were diagnosed with varicella infection during this 10-year period from June 2000 to June 2010 in our live-related renal transplant program, with a median patient age of 39 years (range 21–54 years). Graft dysfunction was observed among five patients following the infection, two of whom became dialysis-dependent. The other three had mild graft dysfunction from which they subsequently recovered, suggesting that infection was responsible for graft dysfunction. None of them developed rejection following exposure or with modification of immunosuppression. All of our patients required admission with 47.8% presenting with various presentations, with orchitis, pancreatitis, encephalitis and gastritis each affecting 8.6% of the patients. All patients were managed with intravenous acyclovir for 2 weeks followed by oral acyclovir for 3 months. The infection was associated with an increased mortality of 13.4% due to superadded infections and central nervous system involvement in one patient with fatal bilateral pneumonia. Conclusions. This infection, which is a benign disease with a largely stable course among the general population, can have severe outcomes for immunocompromised patients, accounting for almost 90% with significant morbidity and mortality in the 8.6% of infected patients, thus highlighting the importance of pre-transplant vaccination in this subgroup of the population. [ABSTRACT FROM PUBLISHER]
- Published
- 2012
- Full Text
- View/download PDF
32. Cystatin C as a Marker of Glomerular Filtration Rate in Voluntary Kidney Donors.
- Author
-
Jaisuresh, Krishnaswamy, Sharma, Raj Kumar, Mehrothra, Sonia, Kaul, Anupma, Badauria, Dharmendra Singh, Gupta, Amit, Prasad, Narayan, and Jain, Apoorva
- Published
- 2012
- Full Text
- View/download PDF
33. Rapidly progressive renal failure—a rare presentation of granulomatous interstitial nephritis due to tuberculosis—case report and review of literature.
- Author
-
Kaul, Anupma, K. Sharma, Raj, Krishnasamy, Jaisuresh, Ruhela, Vivek, and Kumari, Niraj
- Subjects
KIDNEY failure ,DISEASE progression ,INTERSTITIAL nephritis ,RENAL biopsy ,TUBERCULOSIS ,LITERATURE reviews ,INFLAMMATION ,DIAGNOSTIC use of polymerase chain reaction - Abstract
Granulomatous interstitial nephritis (GIN) is a rare manifestation of renal tuberculosis (TB). We report a case of rapidly progressive renal failure (RPRF), granulomatous inflammation of cervical lymph node and GIN as presenting manifestations of TB. Aspiration cytology of cervical lymph node showed granulomatous necrotizing inflammation with acid-fast bacilli (AFB). The renal biopsy and urine specimen did not show AFB. Urine polymerase chain reaction (PCR) for Mycobacterium tuberculosis was positive. We observe that GIN due to TB can present as RPRF and emphasize the value of PCR-based techniques in making a correct diagnosis. [ABSTRACT FROM PUBLISHER]
- Published
- 2011
34. Impact of pre and post transplant 25(OH) Vit-D levels on graft function in living related kidney transplant recipients.
- Author
-
Mehrotra, Sonia, Sharma, Raj Kumar, Patel, Manas R., Gupta, Amit, Prasad, Narayan, Kaul, Anupma, and Bhadauria, Dharmendra Singh
- Published
- 2016
- Full Text
- View/download PDF
35. Late allograft dysfunction secondary to BKV ureteritis in renal transplantation – Can modification of immunosuppression and ureteral stenting be the savior: Case report.
- Author
-
Lal, Hira, Kaul, Anupma, Bhaduaria, Dharmendra, Sharma, R.K., Patel, Manas R., Kumar, Tushant, and Srivastava, A.
- Published
- 2016
- Full Text
- View/download PDF
36. Outcome of renal transplant recipients with CMV and BKV co-infection nephropathy.
- Author
-
Kumar, Shashi, Kaul, Anupma, Prasad, Narayan, Bhadauria, D.S., Gupta, Amit, and Sharma, R.K.
- Published
- 2015
- Full Text
- View/download PDF
37. Opportunistic infection in renal transplant recipients.
- Author
-
Kaul, Anupma and Chauhan, Tejendra Singh
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.